Founded in 2004, CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
At CardioDx, we fuse expertise in genomics, biostatistics, and cardiology to develop objective, reproducible tests that provide clinicians with information to enhance patient care. CardioDx is a privately held company funded by Kleiner, Perkins, Caufield & Byers, TPG Biotech, Mohr Davidow Ventures, Intel Capital and Pappas Ventures.
The following are our guiding principles
- We are committed to improving the quality of patient care
- We continually seek input from physicians on the development of our products and services
- We target our development efforts where genomic tests can enhance cardiovascular patient care
- We develop our products by conducting rigorous clinical studies, employing innovative technologies, and validating the results with independent patient populations
- We deliver clinically validated and reliable products while providing unparalleled customer service
- We safeguard the privacy of all patient information
